Abstract: Thermosettable prepolymers or resins are prepared by reacting (1) a pyrazine compound containing at least two substituent groups which have a hydrogen atom attached to a carbon atom which is attached to the ring such as tetramethylpyrazine, (2) a material containing at least two aromatic aldehyde groups, and (3) at least one of (a) a nitrogen containing aromatic heterocyclic compound containing at least one hydrogen atom attached to a carbon atom attached to the ring and a polymerizable unsaturated group such as 2-methyl-5-vinylpyridine or (b) an aldehyde containing at least one polymerizable unsaturated group such as 4-isopropenyl-1-cyclohexene-1-carboxaldehyde. These prepolymers or resins are curable to thermoset products having good mechanical and thermal properties by heat and pressure or by homopolymerization or copolymerization with N,N'-bis-imides such as 1,1'-(methylenedi-4,1-phenylene)bismaleimide. The prepolymers are suitable for preparing composites.

Abstract: Compounds of Formula (I)S--(CH.sub.2).sub.n --A (I)in whichS is a 17-spartein nucleusn is 0 or 1and A is 2-furyl, 2-thienyl or 2-(N-alkyl)pyrryl when n=0, or 3-furyl or 3-thienyl when n=1, or pyridyl or a phenyl group of Formula (II) ##STR1## in which at least one of R.sub.1, R.sub.2 and R.sub.3 is a defined substituent other than hydrogen. Such compounds and corresponding compounds in which A is an unsubstituted phenyl group are useful in pharmaceutical compositions as heart affecting agents. Methods of preparing such compounds and pharmaceutical compositions are also disclosed.

Abstract: A compound of the formula: ##STR1## wherein R is 2-methylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, an alkyl group of 6 or 7 carbon atoms, or an alkenyl group of 2 to 7 carbon atoms, or a pharmaceutically acceptable salt thereof and processes for preparing the same are provided. The compound can orally be applied as antibiotics having improved absorbability.

Abstract: The crystalline triethylamine salt of cefbuperazone is stable in the dry state and soluble in water and in aqueous injection vehicles.

Abstract: There are disclosed compounds of the formula ##STR1## where X and Y are independently hydrogen, loweralkyl, trifluoromethyl or halogen; Z is --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 CH.sub.2 --; n is 1, 2 or 3; R.sub.1 is hydrogen, loweralkanoyl, aroyl, ethoxycarbonyl, phenoxycarbonyl, loweralkylaminocarbonyl, arylaminocarbonyl, loweralkyl or arylmethyl; R.sub.2 is hydrogen or loweralkyl; R.sub.3 is hydrogen, loweralkyl, ethoxycarbonyl, loweralkanoyl or arylloweralkyl, or R.sub.2 and R.sub.3 taken together is isopropylidene; with the proviso that when n is 3, X, Y and R.sub.1 are all hydrogen and Z is --CH.sub.2 CH.sub.2 --, R.sub.2 and R.sub.3 can not both be methyl. These compounds display antiinflammatory and analgesic activities.

Abstract: Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuro[3,2-e]-isoquinolines and octahydro-4a,7-ethano- and ethenobenzofuro[3,2-e]isoquinolines and processes for their preparation are provided.

Abstract: The present invention relates to new compounds of the formula ##STR1## wherein X is ##STR2## wherein R.sub.1 is hydrogen, lower alkyl, phenyl, benzyl, cinnamoyl, thiophene, furan, pyrrole, imidazole, pyrazole oxazole or thiazole; W is hydrogen or hydroxy; (Y).sub.A is positioned ortho to W and is an aminoloweralkyl having the formula --CH.sub.2 NR.sub.2 R.sub.3 where R.sub.2 and R.sub.3 are the same or different and may be lower alkyl or R.sub.2 and R.sub.3 may together with N form a pyrrolidine, piperidine or azepine ring, and A is 2; n and m are independently from 0 to 5; and R is straight or branched C.sub.1 -C.sub.10 alkyl, straight or branched C.sub.3 -C.sub.10 cycloalkyl, straight or branched C.sub.2 -C.sub.4 alkenyl or straight or branched C.sub.2 -C.sub.4 alkynyl, or a pharmaceutically acceptable salt thereof.These compounds are useful in the treatment of various cardiac arrhythmias.

Abstract: Mitomycin derivatives represented by the formula (I): ##STR1## wherein R.sub.1 and R.sub.2 may be the same or different, and represent a hydrogen atom or a lower alkyl group; R.sub.3 and R.sub.4 mean that when R.sub.3 is a hydrogen atom, R.sub.4 represents --CH.sub.2 OCONH.sub.2 or ##STR2## (wherein R.sub.1 and R.sub.2 have the same significances as defined above), or R.sub.3 and R.sub.4 are combined to form .dbd.CH.sub.2 ; Y and Z may be the same or different, and represent a hydrogen atom or a methyl group; represents .alpha.- or .beta.-bond, provided that Y represents a hydrogen atom when R.sub.4 takes .beta.-configuration, have an excellent anti-tumor activity.

Abstract: Compounds of the formula ##STR1## wherein A, B, C and D are each independently --N.dbd. or --CH.dbd., provided, however, that at least two of them must be --N.dbd., and when A and C are both --N.dbd., at least one or both of B and D must be --N.dbd.; andR.sub.1, R.sub.2 and R.sub.3 are substituents of diverse types;tautomers thereof; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds are useful as cardiotonics.

Abstract: Multi-active photoconductive insulating elements which are sensitive in the far red region of the spectrum are comprised of a charge-generation layer and a charge-transport layer in electrical contact therewith and contain, as the charge-generating agent within the charge-generation layer, the compound N,N'-bis[2-(3-methylphenyl)ethyl]perylene-3,4:9,10-bis(dicarboximide). The charge-generation layer is capable, upon exposure to activating radiation, of highly effective generation and injection of charge carriers and the charge-transport layer, which is comprised of an organic composition containing an organic photoconductive material, is capable of accepting and transporting the injected charge carriers to thereby form a highly advantageous multi-active photoconductive insulating element.

Abstract: Novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula IIIa, ##STR1## wherein: Y is hydrogen or lower alkyl; and Z is an hydroxy substitited 1-pyrrolidinyl radical, ora lower alkyl substituted piperidyl radical, ora 1-piperazinyl radical or an acetamino, acetyl, carbamido, cyano, carboxy lower alkylamino, di-lower alkoxy, nitro, sulfamyl, or lower alkyl substituted anilino radical, ora radical of the formula, ##STR2## wherein R is hydrogen or lower alkyl and R.sup.1 is a nitrogen containing heterocyclic radical selected from the group consisting of amino substituted triazolyl, lower alkyl substituted isothiazolyl, benzothiazolyl, and nitro and halo substituted derivatives of benzothiazolyl, or R.sup.

Abstract: Perylenetetracarbimide mix-crystal pigments in the crystal lattice of the .alpha.- Modification of N,N'-bis-3',5'-dimethylphenylperylenetetracarbimide of the formula (1) comprising 98-70 mole percent of the symmetrical diimide of the formula (1) and correspondingly 2-30 mole percent of at least one asymmetrical diimide of the formula (2) ##STR1## in which R denotes a hydrogen atom or a methyl group.

Abstract: N-Pyrazinyl-haloacetamide having insecticidal, herbicidal, or fungicidal activity. The compound has the general formula: ##STR1## wherein R is hydrogen, hydrocarbyl, halogen, epoxy, hydroxy, alkoxy, mercapto, alkylthio, nitro, cyano or amino; R' is hydrogen or hydrocarbyl; X is halogen; m is an integer from 1 to 4; and n is 0, 1 or 2. The compound may also be a tautomer or acid addition salt of this formula.

Abstract: Process for preparing N-cyano-N'-methyl-1-aziridinoamidine by reacting aziridine with a N-cyano-N'-methyl-O-arylisourea.

Abstract: Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl(CH.sub.2).sub.m --, whereinR.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, andm is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.

Abstract: Substituted trans-1,2-diaminocyclohexyl amide compounds demonstrating selective opioid receptor binding possess utility as analgesic, diuretic, and psychotherapeutic agents. A method of preparing the compounds, pharmaceutical compositions employing the compounds, and a method of alleviating pain employing the compounds are also disclosed.

Abstract: Distamycin A derivatives of formula ##STR1## wherein R is (a)--NHR.sub.3, wherein R.sub.3 is(a')--CON(NO)R.sub.4, in which R.sub.4 is C.sub.1 -C.sub.4 alkyl either unsubstituted or substituted by halogen; or(b') --CO(CH.sub.2).sub.m --R.sub.5, in which R.sub.5 is halogen, oxiranyl, methyloxiranyl, aziridinyl, a group ##STR2## or a group ##STR3## and m is zero or an integer of 1 to 4; or (b) ##STR4## wherein either R.sub.6 and R.sub.7 are the same and are each oxiranemethyl, aziridinemethyl, or C.sub.2 -C.sub.4 alkyl 2-substituted by halogen or by a group --OSO.sub.2 R.sub.8, wherein R.sub.8 is C.sub.1 -C.sub.4 alkyl or phenyl, or one of R.sub.6 and R.sub.7 is hydrogen and the other is as defined above; andeach group R.sub.1 is, independently, hydrogen or C.sub.1 -C.sub.4 alkyl, and the pharmaceutically acceptable salts thereof.The compounds are useful as antiviral or antitumor agents.

Abstract: A series of novel 3-pyrryl fulgides and fulgimides are disclosed which are photochromic. The photochromic compounds are coloured by subjecting them to irradiation in the near ultraviolet and will revert to the colourless form on exposure to visible light, especially light having a wavelength in 600 to 650 nm band.

Abstract: The hydrabamine and benzathine salts of cefamandole are useful in aqueous ophthalmic compositions which have good stability and shelf life.

Abstract: Novel benzopyrano[6,7,8-i,j]quinolizine-11-one lasing dyes and intermediates for their preparation are disclosed.